Related Experiment Video
Updated: Jan 30, 2026

A Pre-clinical Rat Model for the Study of Ischemia-reperfusion Injury in Reconstructive Microsurgery
Published on: November 8, 2019
The damage-associated molecular pattern HMGB1 is released early after clinical hepatic ischemia/reperfusion
Rowan F van Golen1, Megan J Reiniers1, Gerben Marsman2
1Department of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Objective And Background:
Activation of sterile inflammation after hepatic ischemia/reperfusion (I/R) culminates in liver injury. The route to liver damage starts with mitochondrial oxidative stress and cell death during early reperfusion. The link between mitochondrial oxidative stress, damage-associate molecular pattern (DAMP) release, and sterile immune signaling is incompletely understood and lacks clinical validation. The aim of the study was to validate this relation in a clinical liver I/R cohort and to limit DAMP release using a mitochondria-targeted antioxidant in I/R-subjected mice.
Methods:
Plasma levels of the DAMPs high-mobility group box 1 (HMGB1), mitochondrial DNA, and nucleosomes were measured in 39 patients enrolled in an observational study who underwent a major liver resection with (N = 29) or without (N = 13) intraoperative liver ischemia. Circulating cytokine and neutrophil activation markers were also determined. In mice, the mitochondria-targeted antioxidant MitoQ was intravenously infused in an attempt to limit DAMP release, reduce sterile inflammation, and suppress I/R injury.
Results:
In patients, HMGB1 was elevated following liver resection with I/R compared to liver resection without I/R. HMGB1 levels correlated positively with ischemia duration and peak post-operative transaminase (ALT) levels. There were no differences in mitochondrial DNA, nucleosome, or cytokine levels between the two groups. In mice, MitoQ neutralized hepatic oxidative stress and decreased HMGB1 release by ±50%. MitoQ suppressed transaminase release, hepatocellular necrosis, and cytokine production. Reconstituting disulfide HMGB1 during reperfusion reversed these protective effects.
Conclusion:
HMGB1 seems the most pertinent DAMP in clinical hepatic I/R injury. Neutralizing mitochondrial oxidative stress may limit DAMP release after hepatic I/R and reduce liver damage.
Insights
High-mobility group box 1 (HMGB1) is a key damage-associated molecular pattern (DAMP) in liver ischemia/reperfusion (I/R) injury. Targeting mitochondrial oxidative stress with MitoQ reduces HMGB1 release and liver damage in I/R models.
Area of Science:
- Hepatology
- Immunology
- Mitochondrial Medicine
Background:
- Hepatic ischemia/reperfusion (I/R) injury involves sterile inflammation initiated by mitochondrial oxidative stress and damage-associated molecular pattern (DAMP) release.
- The precise link between mitochondrial dysfunction, DAMPs, and sterile immunity in clinical hepatic I/R injury remains unclear.
Purpose of the Study:
- To validate the role of DAMPs in clinical hepatic I/R injury.
- To investigate the therapeutic potential of a mitochondria-targeted antioxidant in mitigating I/R-induced liver damage.
Main Methods:
- Measured plasma levels of DAMPs (HMGB1, mitochondrial DNA, nucleosomes) and inflammatory markers in patients undergoing liver resection with or without I/R.
- Administered MitoQ, a mitochondria-targeted antioxidant, to mice subjected to I/R to assess its effects on DAMP release, sterile inflammation, and liver injury.
Main Results:
- Elevated HMGB1 levels were observed in patients with I/R, correlating with ischemia duration and ALT levels.
- MitoQ administration in mice significantly reduced HMGB1 release, hepatic oxidative stress, hepatocellular necrosis, and transaminase levels.
- Restoring disulfide HMGB1 during reperfusion abolished the protective effects of MitoQ in mice.
Conclusions:
- High-mobility group box 1 (HMGB1) is a critical DAMP in clinical hepatic I/R injury.
- Neutralizing mitochondrial oxidative stress represents a promising strategy to limit DAMP release and reduce liver damage following hepatic I/R.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Fixed Action Patterns
Molecular Models
Energy-releasing Steps of Glycolysis
The first energy-releasing step—the 6th step of glycolysis...
Molecular Orbital Theory II

